Discovery Labs submits IND for respiratory distress syndrome candidate Discovery Laboratories has submitted an investigational new drug application to the FDA to initiate its Aerosurf phase 2 clinical program. The FDA has indicated that the company may initiate the phase 2 clinical program after a 30-day period. Discovery Labs anticipates patient enrollment could begin in Q4. Aerosurf is a novel investigational drug-device combination product being developed to deliver Discovery Labs' KL4 surfactant in aerosolized form to premature infants with respiratory distress syndrome..
News For DSCO From The Last 14 Days
Check below for free stories on DSCO the last two weeks.